Mycoplasma vaccine (Mycoplasma hyopneumoniae, strain J, Inactivated) - search results

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

m+pac mycoplasma hyopneumoniae inactivated vaccine for pigs

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure one mycoplasma hyopneumoniae vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure mycoplasma hyopneumoniae vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ingelvac mycoflex mycoplasma hyopneumoniae inactivated vaccine for pigs

boehringer ingelheim animal health australia pty. ltd. - carbomer; mycoplasma hyopneumoniae - inactivated antigen - misc. vaccines or anti sera - carbomer ungrouped active 1.0 mg; mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 1.0 rp - immunotherapy

European Union - English - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxsafe ms vaccine (living)

bioproperties pty. ltd. - mycoplasma synoviae strain ms-h vaccine, living - misc. aural, ophthalmic, oro/naso pharyngeal - mycoplasma synoviae strain ms-h vaccine, living vaccine-general active 105.7 ccu/dose - immunotherapy - poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | poultry pullets (growing chook) | breeding - airsacculitis | chronic respiratory disease | infectious synovitis | vaccine | equine rotavirus | ms

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

suvaxyn mh - one vaccine (inactivated)

virbac (australia) pty ltd - mycoplasma hyopneumoniae - inactivated antigen; thiomersal - parenteral liquid/solution/suspension - mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 0.0 ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pig - adult - lung lesions | mycoplasma hyopneumoniae | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxsafe mg vaccine (living)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

suvaxyn m.hyo vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure mh/hps vaccine (inactivated)